SynthesisJournal of diabetes investigation2023

Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study.

Dae Jung Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.